Anna Kopińska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5660536/publications.pdf

Version: 2024-02-01

	1684188 1474206		1474206
14	87	5	9
papers	citations	h-index	g-index
14 all docs	14 docs citations	14 times ranked	164 citing authors

#	Article	IF	CITATIONS
1	Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study †PolAZA'. Hematology, 2021, 26, 556-564.	1.5	3
2	Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. Journal of Clinical Apheresis, 2021, 36, 443-453.	1.3	6
3	Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. European Journal of Haematology, 2021, 107, 129-136.	2.2	4
4	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. Polish Archives of Internal Medicine, 2021, 131, 527-534.	0.4	4
5	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Annals of Hematology, 2020, 99, 1845-1853.	1.8	10
6	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	1.4	0
7	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients â‰#60 Years Old (PALG-AML1/2016). Blood, 2020, 136, 3-4.	1.4	O
8	Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 264-274.e4.	0.4	9
9	Hodgkin lymphoma transformation of chronic lymphocytic leukemia—A real life data from the Polish Lymphoma Research Group. Hematological Oncology, 2019, 37, 383-391.	1.7	3
10	Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience. Annals of Hematology, 2019, 98, 1477-1483.	1.8	3
11	Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. Medical Oncology, 2019, 36, 16.	2.5	19
12	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncology Letters, 2019, 18, 5811-5820.	1.8	4
13	Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. Clinical Rheumatology, 2018, 37, 1709-1714.	2.2	10
14	Autologous Haematopoietic Stem Cell Transplantation Is a Highly Effective Second Line of Treatment for Patients with Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 4519-4519.	1.4	12